The presented results showed that CYP2B7P1/2B6 was upregulated in all CRC clinical stages in comparison to the control; the highest fold change was noted for CSIV, which confirmed its involvement in the development of this tumor. This evidence concerns the gene CYP2B7P and neoplasm.